A clinical trial will test autologous hematopoietic stem cell treatment (AHSCT) against the best available biologic therapies for severe forms of relapsing multiple sclerosis (MS). The trial will compare the safety, efficacy, and cost-effectiveness of the 2 therapeutic approaches and has begun enrolling participants.
The Food and Drug Administration (FDA) has approved more than a dozen drugs for the treatment of relapsing forms of MS. These drugs vary in efficacy, safety and cost. For many people with severe forms of relapsing MS, first and second-line drugs fail to adequately control the disease. Previous studies have suggested that AHSCT may be an effective and durable treatment for these individuals, but it has never been formally compared head-to-head with the available third-line drugs, which are highly effective but can have harsh side effects. AHSCT also carries the risks of serious side effects, and even death.
Given these risks and benefits, investigators aim to determine whether AHSCT is an appropriate treatment option for people with severe forms of relapsing MS who would otherwise receive one of the best available third-line biologic drugs.
“For many people with MS—a chronic, debilitating, unpredictable and currently incurable disease—daily life can be a challenge,” said NIAID Director Anthony S. Fauci, MD “AHSCT has the potential to halt the progress of relapsing MS, eliminate the need for a person to take lifelong medication, and allow the body to partially regain function. However, we need to be certain that the benefits of this form of treatment outweigh its serious risks.”
The experimental treatment involves using a mixture of 4 chemical agents to remove these immune cells. Some of the person’s blood-forming stem cells, which were extracted before treatment, are then infused back into the individual. These cells repopulate the immune system, allowing it to reset itself so that the new immune cells no longer attack the central nervous system. This form of treatment is called autologous hematopoietic stem cell transplantation, or AHSCT.
The trial is called BEAT-MS (BEst Available Therapy versus autologous hematopoietic stem cell transplant for Multiple Sclerosis). It is being conducted by the NIAID-funded Immune Tolerance Network (ITN) in collaboration with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). The BMT CTN is funded by the National Heart, Lung, and Blood Institute and the National Cancer Institute, both components of NIH. The lead investigator is Jeffrey A. Cohen, MD, a professor of neurology at the Cleveland Clinic Lerner College of Medicine and the director of the Experimental Therapeutics Program in the Mellen Center for Multiple Sclerosis Treatment and Research at the Cleveland Clinic.
BEAT-MS will enroll 156 adults ages 18 to 55 years at 19 sites in the US and the UK. Participants will be randomly assigned to receive either AHSCT or one of the best available high-efficacy biologic drugs, and then will be followed for 6 years. The neurologists who periodically examine the participants and assess their level of disability will not know which type of treatment they were assigned.
The main outcome investigators will measure is how much time elapses between a participant’s assignment to a treatment strategy and MS relapse or death from any cause, if either of these occur, during the first 3 years of the follow-up period. The mechanisms of action of the 2 treatment strategies will be examined and compared to the newly developing immune systems of participants who receive AHSCT with the immunologic features of participants who receive the best available biologic drugs. Investigators will compare the effects of the 2 treatment strategies on other measures of disease activity and severity, cost-effectiveness in terms of health care costs and individual productivity, and participants’ quality of life.
Crystal Dixon, MD, Miguel Melo-Bicchi, MD, and Kottil W. Rammohan, MD
Michael V. Robers, MD, Deepak Soneji, MD, PhD, and Lilyana Amezcua, MD, MS
Brian Barry, MD, and Robert K. Shin, MD